{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:22:58Z","timestamp":1791868978789,"version":"4.3.4"},"reference-count":32,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2016,9,21]],"date-time":"2016-09-21T00:00:00Z","timestamp":1474416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:sec><jats:title>Disease overview<\/jats:title><jats:p>Approximately one\u2010fourth of cutaneous lymphomas are B\u2010cell derived and are generally classified into three distinct subgroups: primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), and primary cutaneous diffuse large B\u2010cell lymphoma, leg type (PCDLBCL, LT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Diagnosis<\/jats:title><jats:p>Diagnosis and disease classification is based on histologic review and immunohistochemical staining of an appropriate skin biopsy. Pathologic review and an appropriate staging evaluation are necessary to distinguish primary cutaneous B\u2010cell lymphomas from systemic B\u2010cell lymphomas with secondary skin involvement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Risk\u2010stratification<\/jats:title><jats:p>Disease histology remains the most important prognostic determinant. Both PCFCL and PCMZL are indolent lymphomas that infrequently disseminate to extracutaneous sites and are associated with 5\u2010year survival rates that exceed 95%. In contrast, PCDLBCL, LT is an aggressive lymphoma with an inferior prognosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Risk\u2010adapted therapy<\/jats:title><jats:p>PCFCL and PCMZL patients with solitary or relatively few skin lesions may be affectively managed with local radiation therapy. While single\u2010agent rituximab may be employed for patients with more widespread skin involvement, multiagent chemotherapy is rarely appropriate. In contrast, management of patients with PCDLBCL, LT is comparable to the management of patients with systemic DLBCL. Am. J. Hematol. 91:1052\u20131055, 2016. \u00a9 2016 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ajh.24462","type":"journal-article","created":{"date-parts":[[2016,9,21]],"date-time":"2016-09-21T06:20:42Z","timestamp":1474438842000},"page":"1052-1055","source":"Crossref","is-referenced-by-count":22,"title":["Cutaneous <scp>B<\/scp>\u2010cell lymphomas: 2016 update on diagnosis, risk\u2010stratification, and management"],"prefix":"10.1002","volume":"91","author":[{"given":"Ryan A.","family":"Wilcox","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology University of Michigan Cancer Center 1500 E. Medical Center Drive Room 4310 CC Ann Arbor Michigan 48109\u20105948"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,9,21]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3502"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184168"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-10-054601"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202x.2001.01543.x"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1594"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.1995.tb00766.x"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12371768"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.12.3922"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.9.1144"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.6396"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.10104"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.265"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.821"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.04.018"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.1997.tb01318.x"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2000.01003.x"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200009000-00012"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0560.2001.281002.x"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07159.x"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.137"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6285"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.07.019"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2726"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.22720.x"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.16.3602"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-152850"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2471"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09798.x"},{"key":"e_1_2_5_30_1","first-page":"391","article-title":"Topical imiquimod as treatment for different kinds of cutaneous lymphoma","volume":"16","author":"Coors EA","year":"2006","journal-title":"Eur J Dermatol"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0303-6987.2006.00544.x"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-013-1787-0"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.4081\/rt.2015.6067"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.24462","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.24462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T20:45:59Z","timestamp":1695501959000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.24462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,21]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1002\/ajh.24462"],"URL":"https:\/\/doi.org\/10.1002\/ajh.24462","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,21]]}}}